NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Forecast, Price & News $28.20 +0.71 (+2.58%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$27.27▼$28.2650-Day Range$18.02▼$28.2052-Week Range$6.91▼$28.26Volume725,409 shsAverage Volume918,301 shsMarket Capitalization$1.61 billionP/E RatioN/ADividend YieldN/APrice Target$35.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Protagonist Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside26.5% Upside$35.67 Price TargetShort InterestHealthy6.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.34) to ($2.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector376th out of 983 stocksPharmaceutical Preparations Industry179th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.67, Protagonist Therapeutics has a forecasted upside of 26.5% from its current price of $28.20.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.29% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 3.1 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Protagonist Therapeutics this week, compared to 2 articles on an average week.Search Interest10 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows4 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions91.51% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.34) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 7.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Protagonist Therapeutics (NASDAQ:PTGX) StockProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.Read More Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Stock News HeadlinesJune 2, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceJune 1, 2023 | finance.yahoo.comProtagonist Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceJune 4, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 26, 2023 | finance.yahoo.comHow Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%May 26, 2023 | msn.comHere's What Could Help Protagonist Therapeutics (PTGX) Maintain Its Recent Price StrengthMay 25, 2023 | seekingalpha.comProtagonist Therapeutics Sees Steady If Bumpy ProgressMay 22, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Research Coverage Started at StockNews.comMay 12, 2023 | finance.yahoo.comPromising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation TreatmentJune 4, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 12, 2023 | finance.yahoo.comProtagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113May 11, 2023 | finance.yahoo.comProtagonist Therapeutics to Participate in the JMP Securities Life Sciences ConferenceMay 11, 2023 | finance.yahoo.comProtagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology AssociationMay 10, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Protagonist Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:PTGX)May 5, 2023 | msn.comUnusual Put Option Trade in Protagonist Therapeutics (PTGX) Worth $476.38KMay 4, 2023 | msn.comProtagonist Therapeutics: Q1 Earnings InsightsApril 28, 2023 | msn.comHC Wainwright & Co. Reiterates Protagonist Therapeutics (PTGX) Buy RecommendationApril 27, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Protagonist TherapeuticsApril 18, 2023 | markets.businessinsider.comProtagonist Therapeutics (PTGX) Receives a Buy from JMP SecuritiesApril 17, 2023 | finance.yahoo.comProtagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share PriceApril 14, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Trading 4.3% Higher April 8, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Trading 3.9% Higher April 7, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down to $21.55April 6, 2023 | markets.businessinsider.comProtagonist Therapeutics Declines 8% After Pricing 5 Mln Share OfferingApril 5, 2023 | markets.businessinsider.comWhy Protagonist Therapeutics Shares Are NosedivingApril 5, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common StockApril 5, 2023 | msn.comProtagonist Therapeutics prices $100M offeringApril 5, 2023 | finance.yahoo.comProtagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common StockSee More Headlines PTGX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Company Calendar Last Earnings3/15/2023Today6/04/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.67 High Stock Price Forecast$41.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+26.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-127,390,000.00 Net MarginsN/A Pretax Margin-16,319.91% Return on Equity-59.44% Return on Assets-51.90% Debt Debt-to-Equity RatioN/A Current Ratio10.15 Quick Ratio10.15 Sales & Book Value Annual Sales$859,000.00 Price / Sales1,879.49 Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book7.46Miscellaneous Outstanding Shares57,251,000Free Float54,388,000Market Cap$1.61 billion OptionableNot Optionable Beta1.97 Key ExecutivesDinesh V. PatelPresident, Chief Executive Officer & DirectorAsif AliChief Financial Officer & Executive Vice PresidentMohammad MasjedizadehChief Technical Officer & Executive VPArturo MolinaChief Medical OfficerMatthew M. GoslingExecutive Vice President & General CounselKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXKeros TherapeuticsNASDAQ:KROSArcus BiosciencesNYSE:RCUSDynavax TechnologiesNASDAQ:DVAXDICE TherapeuticsNASDAQ:DICEView All CompetitorsInstitutional OwnershipProShare Advisors LLCBought 8,886 shares on 5/26/2023Ownership: 0.016%Ameriprise Financial Inc.Bought 18,358 shares on 5/22/2023Ownership: 0.032%JPMorgan Chase & Co.Sold 197,029 shares on 5/18/2023Ownership: 0.185%Financial Enhancement Group LLCBought 41,818 shares on 5/17/2023Ownership: 0.073%Fred Alger Management LLCBought 11,605 shares on 5/16/2023Ownership: 0.020%View All Institutional Transactions PTGX Stock - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 12-month target prices for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $28.00 to $41.00. On average, they anticipate the company's stock price to reach $35.67 in the next year. This suggests a possible upside of 26.5% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2023? Protagonist Therapeutics' stock was trading at $10.91 at the start of the year. Since then, PTGX stock has increased by 158.5% and is now trading at $28.20. View the best growth stocks for 2023 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.02. What ETFs hold Protagonist Therapeutics' stock? ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include Innovator IBD Breakout Opportunities ETF (BOUT), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA Healthcare Momentum ETF (PTH), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), BlackRock Future Health ETF (BMED) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.04%), BlackRock Inc. (7.69%), BVF Inc. IL (6.60%), Farallon Capital Management LLC (4.57%), State Street Corp (4.22%) and Dimensional Fund Advisors LP (2.20%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $28.20. How much money does Protagonist Therapeutics make? Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.61 billion and generates $859,000.00 in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. How many employees does Protagonist Therapeutics have? The company employs 118 workers across the globe. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com. This page (NASDAQ:PTGX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.